Brought to you by 
CombinatoRx, Angiotech in combination drug discovery alliance
12 Oct 2005
Executive Summary
CombinatoRx (combines approved drugs to simultaneously target multiple disease pathways and create effects that are different from those of each drug alone) and Angiotech Pharmaceuticals (drug-coated medical devices and biomaterials) will jointly discover and develop local drug/device combinations in fields of interest to Angiotech. These areas will initially be vascular and orthopedic disorders, surgical adhesions, and local tumor management.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CombinatoRx, Angiotech in combination drug discovery alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice